Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 133.00 | |
5 mg | In stock | $ 302.00 | |
10 mg | In stock | $ 453.00 | |
25 mg | In stock | $ 747.00 | |
50 mg | In stock | $ 1,050.00 | |
100 mg | In stock | $ 1,420.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 448.00 |
Description | AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively). |
Targets&IC50 | EGFR:4 nM , ErbB2:3 nM , ERB3:4 nM |
In vivo | AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth[1]. |
Animal Research | Two IBC cell lines SUM149 and FC-IBC-02 。Cell growth and apoptotic cell death were examined in vitro.?For the in vivo tumor growth studies, IBC cells were orthotopically transplanted into the mammary fat pads of immunodeficient mice.?AZD8931 was given by daily oral gavage at doses of 25 mg/kg, 5 days/week for 4 weeks.?Paclitaxel was subcutaneously injected twice weekly[1]. |
Molecular Weight | 706.1 |
Formula | C31H33ClFN5O11 |
CAS No. | 1196531-39-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (42.49 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AZD8931 diFuMaric acid 1196531-39-1 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR AZD-8931 diFuMaric acid inhibitor inhibit